{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:50:57Z","timestamp":1770727857451,"version":"3.49.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019212","name":"American Academy of Allergy, Asthma and Immunology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaip.2022.08.033","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T22:48:46Z","timestamp":1662158926000},"page":"3057-3063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-2323","authenticated-orcid":false,"given":"Justin","family":"Greiwe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Honsinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hvisdas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Nicklas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea J.","family":"Apter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.08.033_bib1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.mayocp.2012.04.017","article-title":"Ten common questions (and their answers) about off-label drug use","volume":"87","author":"Wittich","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2022.08.033_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40264-017-0526-1","article-title":"Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals","volume":"40","author":"Schick","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2022.08.033_bib3","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2017.5150","article-title":"Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010","volume":"317","author":"Downing","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.08.033_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pds.1193","article-title":"FDA drug prescribing warnings: is the black box half empty or half full?","volume":"15","author":"Wagner","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaip.2022.08.033_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3163\/1536-5050.95.2.224","article-title":"Medwatch: the FDA safety information and adverse event reporting program","volume":"95","author":"Craigle","year":"2007","journal-title":"J\u00a0Med Libr Assoc"},{"key":"10.1016\/j.jaip.2022.08.033_bib6","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products\u2014content and format. Accessed July 20, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/warnings-and-precautions-contraindications-and-boxed-warning-sections-labeling-human-prescription"},{"key":"10.1016\/j.jaip.2022.08.033_bib7","series-title":"FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis","author":"US Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.jaip.2022.08.033_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaip.2020.07.052","article-title":"Risk of psychiatric adverse events among montelukast users","volume":"9","author":"Sansing-Foster","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.033_bib9","unstructured":"Kelly KJ. FDA removes Black Box Warning from varenicline\u2019s label. NEJM Journal Watch. Accessed December 4, 2022. https:\/\/www.jwatch.org\/fw112367 \/2016\/12\/19\/fda-removes-black-box-warning-vareniclines-label"},{"key":"10.1016\/j.jaip.2022.08.033_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.anai.2014.05.017","volume":"113","author":"Dinakar","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.08.033_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 Focused Updates to the Asthma Management Guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib14","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/j.jaip.2021.09.035","article-title":"Translating evidence to optimize patient care using GRADE","volume":"9","author":"Chu","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.033_bib15","article-title":"Trustworthy patient-centered guidelines: insights from atopic dermatitis and a proposal for the future","volume":"7","author":"Agarwal","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract. Published July"},{"key":"10.1016\/j.jaip.2022.08.033_bib16","unstructured":"U.S. Food & Drug Administration. Prescription drug labeling resources. Updated February 24, 22. Accessed March 30, 2022. https:\/\/www.fda.gov\/drugs\/laws-acts-and-rules\/prescription-drug-labeling-resources"},{"key":"10.1016\/j.jaip.2022.08.033_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.acap.2008.11.010","article-title":"Off-label prescribing to children in the United States outpatient setting","volume":"9","author":"Bazzano","year":"2009","journal-title":"Acad Pediatr"},{"key":"10.1016\/j.jaip.2022.08.033_bib18","first-page":"476","article-title":"Off-label prescribing: a call for heightened professional and government oversight","volume":"37","author":"Dresser","year":"2009","journal-title":"J\u00a0Law Med Ethics"},{"key":"10.1016\/j.jaip.2022.08.033_bib19","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/art.10426","article-title":"The safety of celecoxib in patients with aspirin-sensitive asthma","volume":"46","author":"Woessner","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2022.08.033_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/0976-500X.130046","article-title":"Off-label use of medicine: perspective of physicians, patients, pharmaceutical companies and regulatory authorities","volume":"5","author":"Gupta","year":"2014","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.jaip.2022.08.033_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2146\/ajhp130786","article-title":"Implementation of a comprehensive medication prior-authorization service","volume":"72","author":"Leinss","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaip.2022.08.033_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib23","doi-asserted-by":"crossref","first-page":"g3596","DOI":"10.1136\/bmj.g3596","article-title":"Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study","volume":"348","author":"Lu","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2022.08.033_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaci.2005.08.060","article-title":"The \u201cblack box\u201d warning and allergy drugs","volume":"117","author":"Aaronson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/bmj.306.6884.1034","article-title":"Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment","volume":"306","author":"Castle","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2022.08.033_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1378\/chest.129.1.15","article-title":"The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol","volume":"129","author":"Nelson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2022.08.033_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0091-7435(78)90265-7","article-title":"Association between asthma mortality and isoproterenol aerosols: a review","volume":"7","author":"Stolley","year":"1978","journal-title":"Prev Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(89)92505-1","article-title":"Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study","volume":"1","author":"Crane","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.08.033_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7326\/0003-4819-127-2-199707150-00009","article-title":"Observations on asthma mortality","volume":"127","author":"McFadden","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib30","unstructured":"Centers for Disease Control and Prevention. Accessed April 1, 2022. www.cdc.gov"},{"key":"10.1016\/j.jaip.2022.08.033_bib31","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJM199412083312302","article-title":"Patterns of asthma mortality in Philadelphia: 1969-1991","volume":"331","author":"Lang","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1081-1206(10)62200-4","article-title":"2001: the asthma odyssey","volume":"87","author":"Lang","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5694\/j.1326-5377.1996.tb122082.x","article-title":"Asthma mortality: where is it going?","volume":"164","author":"Wilson","year":"1996","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaip.2022.08.033_bib34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/bmj.314.7092.1439","article-title":"Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study","volume":"314","author":"Campbell","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.jaip.2022.08.033_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0091-6749(00)90180-5","article-title":"Decrease in asthma mortality rate in Israel from 1991-1995: Is it related to increased use of inhaled corticosteroids?","volume":"105","author":"Goldman","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1513\/pats.2306028","article-title":"Pharmacologic interventions to reduce the risk of asthma exacerbations","volume":"1","author":"O\u2019Byrne","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.jaip.2022.08.033_bib37","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199711133372001","article-title":"Effect of inhaled formoterol and budesonide on exacerbations of asthma","volume":"337","author":"Pauwels","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib38","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1164\/ajrccm.164.8.2104102","article-title":"Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial","volume":"164","author":"O\u2019Byrne","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(94)92996-3","article-title":"Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid","volume":"344","author":"Greening","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.08.033_bib40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1164\/ajrccm.153.5.8630590","article-title":"Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids","volume":"153","author":"Woolcock","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001385","article-title":"Long-acting beta2-agonists for stable chronic asthma","volume":"3","author":"Walters","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2022.08.033_bib43","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bmj.320.7246.1368","article-title":"Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)","volume":"320","author":"Shrewsbury","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2022.08.033_bib44","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/thx.2004.039180","article-title":"Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroid in symptomatic asthma","volume":"60","author":"Masoli","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.08.033_bib45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.292.3.367","article-title":"Pharmacological management to reduce exacerbations in adults with asthma. A systematic review and meta-analysis","volume":"292","author":"Sin","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.08.033_bib46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/rmed.2000.0876","article-title":"Cost-effectiveness of salmeterol\/fluticasone propioinate combination product 50\/250 microgram twice daily and budesonide 800 microgram twice daily in the treatment of adults and adolescents with asthma","volume":"94","author":"Lundb\u00e4ck","year":"2000","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib47","doi-asserted-by":"crossref","first-page":"904","DOI":"10.7326\/0003-4819-144-12-200606200-00126","article-title":"Meta-analysis: effect of long acting beta agonists on severe asthma exacerbations and asthma-related deaths","volume":"144","author":"Salpeter","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0895-4356(95)00555-2","article-title":"Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients","volume":"49","author":"Mann","year":"1996","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jaip.2022.08.033_bib49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1164\/ajrccm.158.3.9803047","article-title":"Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol","volume":"158","author":"Lanes","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/thx.53.1.7","article-title":"A\u00a0case control study of salmeterol and near fatal attacks of asthma","volume":"53","author":"Williams","year":"1998","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.08.033_bib51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thorax.57.8.683","article-title":"Respiratory medications and risk of asthma death","volume":"57","author":"Lanes","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.08.033_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/bmj.38316.729907.8F","article-title":"Bronchodilator treatment and deaths from asthma: case control study","volume":"330","author":"Anderson","year":"2005","journal-title":"Br Med J"},{"key":"10.1016\/j.jaip.2022.08.033_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jaci.2005.11.012","article-title":"Molecular mechanisms of \u00df2-adrenergic receptor function, response, and regulation","volume":"117","author":"Johnson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1164\/rccm.200412-1635OE","article-title":"How pharmacogenetics will play a role in the management of asthma","volume":"172","author":"Wechsler","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib55","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thorax.55.9.762","article-title":"Asthma exacerbations during long term beta agonist use: influence of beta 2 adrenoceptor polymorphism","volume":"55","author":"Taylor","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.08.033_bib56","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1716868","article-title":"Combined analysis of asthma safety trials of long-acting \u03b22-agonists","volume":"378","author":"Busse","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib57","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMp1716858","article-title":"Inhaled corticosteroids and LABAs\u2014removal of the FDA\u2019s Boxed Warning","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib58","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.2010.310","article-title":"Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis","volume":"303","author":"Bassler","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.08.033_bib59","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1056\/NEJMp058299","article-title":"Safety of long-acting beta-agonists--an urgent need to clear the air","volume":"353","author":"Martinez","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib60","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJMp0810561","article-title":"Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values","volume":"360","author":"Kramer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib61","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMe0902057","article-title":"Risks of long-acting beta-agonists in achieving asthma control","volume":"360","author":"Drazen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib62","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1002074","article-title":"The FDA and safe use of long-acting beta-agonists in the treatment of asthma","volume":"362","author":"Chowdhury","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib63","article-title":"Neuropsychiatric reactions with the use of montelukast","volume":"376","author":"Ekhart","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2022.08.033_bib64","article-title":"Neuropsychiatric events with use of montelukast in pediatric patients","volume":"27","author":"Document","year":"2019","journal-title":"Pediatric Advisory Committee Meeting; September"},{"key":"10.1016\/j.jaip.2022.08.033_bib65","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib66","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1081-1206(10)60091-9","article-title":"Omalizumab in idiopathic anaphylaxis","volume":"102","author":"Warrier","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11882-021-00988-y","article-title":"Idiopathic anaphylaxis: a perplexing diagnostic challenge for allergists","volume":"21","author":"Gulen","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2022.08.033_bib69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.033_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.08.033_bib72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaip.2014.10.010","article-title":"The use of anti-IgE therapy beyond allergic asthma","volume":"3","author":"Stokes","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.033_bib73","series-title":"FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder. [Press release]","year":"2022"},{"key":"10.1016\/j.jaip.2022.08.033_bib74","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/09546634.2020.1853024","article-title":"Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jaip.2022.08.033_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13222","article-title":"Dupilumab for prurigo nodularis: case series and review of the literature","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2022.08.033_bib76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/cod.14104","article-title":"The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis\u201452 week results from the Dutch BioDay Registry","volume":"87","author":"Voorberg","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2022.08.033_bib77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2018.07.043","article-title":"Dupilumab use in allergic contact dermatitis","volume":"80","author":"Machler","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.08.033_bib78","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.936488","article-title":"Long-term efficacy of dupilumab in alopecia areata","volume":"23","author":"Kulkarni","year":"2022","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jaip.2022.08.033_bib79","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1001\/jama.2016.3070","article-title":"The new era of informed consent: getting to a reasonable-patient standard through shared decision making","volume":"315","author":"Spatz","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.08.033_bib80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archinternmed.2009.454","article-title":"Improving prescription medication warnings to promote patient comprehension","volume":"170","author":"Wolf","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib81","unstructured":"US Food and Drug Administration. The impact of direct-to-consumer advertising. Published November 3, 2018. Accessed December 12, 2022. https:\/\/www.fda.gov\/drugs\/information-consumers-and-patients-drugs\/impact-direct-consumer-advertising"},{"issue":"133","key":"10.1016\/j.jaip.2022.08.033_bib82","first-page":"131","article-title":"Should Canada allow direct-to-consumer advertising of prescription drugs? No","volume":"55","author":"Mintzes","year":"2009","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.jaip.2022.08.033_bib83","doi-asserted-by":"crossref","first-page":"887","DOI":"10.7326\/0003-4819-145-12-200612190-00144","article-title":"Literacy and misunderstanding prescription medication labels","volume":"145","author":"Davis","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib84","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11606-017-4274-9","article-title":"Direct-to-consumer broadcast advertisements for pharmaceuticals: off-label promotion and adherence to FDA guidelines","volume":"33","author":"Klara","year":"2018","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib85","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2021.7872","article-title":"Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.08.033_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/d41573-021-00002-0","article-title":"2020 FDA drug approvals","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaip.2022.08.033_bib87","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1377\/hlthaff.2014.0122","article-title":"Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals","volume":"33","author":"Frank","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jaip.2022.08.033_bib88","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJMsa0706341","article-title":"Drug-review deadlines and safety problems","volume":"358","author":"Carpenter","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.033_bib89","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0896","article-title":"Trends in off-label drug use in ambulatory settings: 2006-2015","volume":"144","author":"Hoon","year":"2019","journal-title":"Pediatrics"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822008716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822008716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:37:47Z","timestamp":1761975467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822008716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2213219822008716"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.08.033","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}